Brainscope just agreed an IP based funding arrangement from AON providing $35 million in capital to fund the full expansion of its commercial activities.
BrainScope can confirm the likelihood of a brain bleed with 99% sensitivity to the smallest detectable level of blood (>1 mL). Brainscope said ‘this paves the way for rapid commercial expansion in hospital emergency departments of the first FDA cleared system for rapid assessment of brain bleeds and concussions’.
Brainscopes IP includes 87 issued patents, h››¢›ardware, trade secrets, know how, alogorithms and substantial data from the 14 years of effort. For example BrainScope’s database contains more than 13,000 evaluations from patients and normal subjects. 10,000 features that characterize the EEG signal are extracted from each record and age-regressed relative to age expected normal values. These features are then used to power proprietary, A.I. derived FDA cleared algorithms to create objective biomarkers of brain injury.
Lewis Lee, CEO of Aon’s Intellectual Property Solutions said, "We are excited to help IP-rich companies like BrainScope unlock the value of these assets and provide them greater access to capital so they can further pursue their growth ambitions without diluting their ownership."
“Innovation is the key to a growth economy, but intangible assets are the foundation. That is why we are bringing unique solutions to the market to help growth stage companies like BrainScope maximize the value of their intellectual property,”
#IPfunding #AON #Brainscope #startup #technology
COPYRIGHT PROTECTED © 2019 - 2022 Exalt IP Limited. All rights reserved.
Author: John Pryor Exalt IP